Halozyme Therapeutics | HALO - Selling And Administration Expenses


Halozyme Therapeutics reported $57M in Selling and Administration Expenses for its fiscal quarter ending in June of 2026.





Selling And Administration Expenses Change Date
Acadia Pharmaceuticals USD 148.57M 12.22M Jun/2026
Agios Pharmaceuticals USD 38.46M 4.51M Mar/2026
Alnylam Pharmaceuticals USD 347.92M 65.41M Jun/2026
Amarin USD 18.97M 1.03M Dec/2025
Amgen USD 1.72B 134M Jun/2026
Baxter International USD 735M 7M Jun/2026
Cara Therapeutics USD 2.09M 96K Mar/2026
Cytokinetics USD 104.4M 499K Jun/2026
DBV Technologies USD 13.4M 8.14M Mar/2026
Eli Lilly USD 3.43B 496M Jun/2026
Halozyme Therapeutics USD 57M 10.71M Jun/2026
Intrexon USD 10.31M 41K Jun/2024
Ionis Pharmaceuticals USD 130.07M 20.92M Jun/2026
MannKind USD 58.3M 4.22M Jun/2026
Minerva Neurosciences USD 2.48M 58.79K Sep/2024
Nektar Therapeutics USD 11.87M 1.7M Mar/2026
Pfizer USD 3.41B 496M Jun/2026
Rigel Pharmaceuticals USD 27.04M 1M Sep/2024
United Therapeutics USD 206.7M 50.1M Jun/2026
Vanda Pharmaceuticals USD 39.28M 1.71M Dec/2024